It’s been an amazing ride for the share price of Dynavax Technologies Corporation (NASDAQ: DVAX) since the start of this year, with a year-to-date change of -2.39. The price performance is recorded at -65.38% in the last full year of trading. As of the most recent market close, this stock’s last recorded price was $6.76. But how does this particular stock’s price movements compare to the rest of the market? One metric that indicates how volatile a stock’s price is compared to the wider market is the Beta. The Beta value for Dynavax Technologies Corporation (NASDAQ: DVAX) is 0.56 indicating less volatile than the rest of the market.
If we get into the details of the Technical Analysis for the period, in last 20-day duration stock’s Moving Average was 6.77 and the Average Volume of this company’s shares was 995,185.
An additional method of evaluating the price evolution of a public organization’s stock is to check out its Return on Investment (ROI), which illustrates overall investment performance. It’s also utilized as a way of observing the strength of one investment compared to another, side-by-side. At the time of writing, the ROI for stock is -93.50%.
An additional way that expert traders determine a stock’s volatility is by looking at its Average True Range (ATR) – a highly useful tool that enables investors to create a whole trading strategy or to simply figure out tactical entry or exit signals. This volatility measurement has been looked to for several years as a way to generate the best trading results. This stock’s ATR was 0.47 on this particular day.
Now let’s take a more in-depth look at DVAX technical analysis metrics. The Moving Average Convergence Divergence (MACD) is one of the indicators that investors use the most often, as it is widely seen as one of the easiest and most helpful measurements of both the momentum and general trend in markets. The MACD Oscillator for Dynavax Technologies Corporation through the last 20-day time span was posted at 0.44.
Then another helpful metric, the Williams’ Percent Range Technical Indicator (seen as %R) is looked at to guide investors as to whether the shares are oversold or overbought – and is very much the same as the Stochastic Oscillator. The major difference is that %R shows us the level of the closing price in relation to the highest price point for the period concerned. Its %R through the last 20-day stretch was 72.59%.
Additionally, during that same period of time, the Relative Strength Index for Dynavax Technologies Corporation (NASDAQ: DVAX) is 44.68%. A Relative Strength Index (RSI) below 30% is considered oversold, while it is seen as overbought if it rises above 70%.
Halozyme Therapeutics, Inc.(NASDAQ: HALO) common stock has recently come under the judgmental eyes of top market analysts. For this stock’s full-year price projection, 9 different trading experts have reported their forecasts. For the full-year period that ends on Dec-19, analysts are in agreement that this publicly-traded organization’s mean sales will reach $205.49 million.
According to Thomson Reuter’s data, of all the analysts covering this stock, 2 have recommended shares of Halozyme Therapeutics, Inc. a BUY, 3 have suggested OUTPERFORM, 3 were telling investors to HOLD and only 1 analyst is giving a Sell recommendation.
Three months prior to today, 2 analysts were rating this stock as a BUY, 3 were reporting it as an OUTPERFORM, 4 were recommending that investors HOLD, and 1 said the stock has a SELL rating.
Let’s dig into the minute details of Halozyme Therapeutics, Inc. (NASDAQ: HALO) technical analysis. This Company’s Year-to-Date Moving Average is currently sitting at 16.31. The average number of shares that changed owners during this 12-month period was observed to be 1,073,896.How does that compare to the latest trading session?
At the most recent market open, the per-share price of Halozyme Therapeutics, Inc. (NASDAQ: HALO) common stock was $15.59. Before the end of the trading session, this stock’s price rose as high as $15.92 and dropped to as low as $15.49.
During the most recent full trading session, shares of HALO generated a trading volume of 1,231,456 shares, in contrast with its usual average daily volume of 806.84K shares.
Taking a look backward at trading activity from the last 9-day period, Halozyme Therapeutics, Inc. (NASDAQ: HALO) has demonstrated an Average True Range value of 0.55. During the last 14-day stretch, this company’s ATR was posted at 0.54. Meanwhile, during the last 20 days, it was 0.54, with the last 100-day figure being 0.60.